| Literature DB >> 20049130 |
Irina Mordukhovich1, Elissa Wilker, Helen Suh, Robert Wright, David Sparrow, Pantel S Vokonas, Joel Schwartz.
Abstract
BACKGROUND: Particulate matter (PM) air pollution has been associated with cardiovascular morbidity and mortality, and elevated blood pressure (BP) is a known risk factor for cardiovascular disease. A small number of studies have investigated the relationship between PM and BP and found mixed results. Evidence suggests that traffic-related air pollution contributes significantly to PM-related cardiovascular effects.Entities:
Keywords: black carbon; blood pressure; epidemiology; gene–environment interactions; human; oxidative stress; particulate matter
Mesh:
Substances:
Year: 2009 PMID: 20049130 PMCID: PMC2801196 DOI: 10.1289/ehp.0900591
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Descriptive statistics at baseline for participants with information on BC (n = 461) and PM2.5 concentrations (n = 457).
| Study variable | Subjects with BC | Subjects with PM2.5 |
|---|---|---|
| BC (μg/m3) | 1.10 ± 0.43 | 1.06 ± 0.44 |
| PM2.5 (μg/m3) | 12.15 ± 4.98 | 12.06 ± 4.93 |
| Age (years) | 71.16 ± 6.46 | 72.18 ± 6.74 |
| Body mass index (kg/m2) | 28.07 ± 3.89 | 27.95 ± 3.92 |
| Smoking status [no. (%)] | ||
| Never-smoker | 114 (29.53) | 116 (28.86) |
| Former smoker | 259 (67.10) | 269 (66.92) |
| Current smoker | 13 (3.37) | 17 (4.23) |
| Lifetime smoking (pack-years) | 27.38 ± 23.05 | 28.25 ± 23.77 |
| Alcohol intake (≥ 2 drinks/day) [no. (%)] | 76 (19.69) | 80 (19.90) |
| Temperature (°C) | 12.18 ± 7.49 | 11.76 ± 7.85 |
| Relative humidity (%) | 68.70 ± 8.74 | 69.61 ± 8.60 |
| Antihypertensive medication [no. (%)] | ||
| Any | 215 (55.70) | 243 (60.45) |
| Calcium channel blockers | 45 (11.66) | 50 (12.44) |
| Angiotensin-converting enzyme inhibitors | 67 (17.36) | 80 (19.90) |
| Angiotensin receptor agonists | 19 (4.92) | 22 (5.47) |
| Beta blockers | 114 (29.53) | 127 (31.59) |
| Alpha blockers | 46 (11.92) | 59 (14.68) |
| Diuretics | 69 (17.88) | 81 (20.15) |
| Statin use [no. (%)] | 118 (30.57) | 131 (32.59) |
| Season of clinical visit [no. (%)] | ||
| Spring | 90 (23.32) | 101 (25.12) |
| Summer | 80 (20.73) | 102 (25.37) |
| Fall | 145 (37.56) | 119 (29.60) |
| Winter | 71 (18.39) | 80 (19.90) |
| Weekday of clinical visit [no. (%)] | ||
| Monday | 22 (5.70) | 11 (2.74) |
| Tuesday | 91 (23.58) | 103 (25.62) |
| Wednesday | 161 (41.71) | 198 (49.25) |
| Thursday | 112 (29.02) | 90 (22.39) |
| Diabetes [no. (%)] | 41 (10.62) | 47 (11.69) |
| Race/ethnicity [no. (%)] | ||
| Non-Hispanic white | 376 (97.41) | 391 (97.26) |
| Non-Hispanic black | 6 (1.55) | 7 (1.74) |
| Hispanic white | 3 (0.78) | 3 (0.75) |
| Hispanic black | 1 (0.26) | 1 (0.25) |
| Years of education | 14.58 ± 2.70 | 14.65 ± 2.71 |
| Fasting plasma glucose (mmol) | 106.97 ± 25.30 | 106.03 ± 23.85 |
| BP (mmHg) | ||
| SBP | 132.44 ± 16.60 | 131.21 ± 17.26 |
| DBP | 77.75 ± 8.96 | 76.46 ± 9.55 |
Values are mean ± SD or no. (%).
Seven-day moving average.
Mean concentration reported across all study visits rather than just at baseline (1,067 clinical visits for BC, 949 clinical visits for PM2.5).
Mixed linear effects models estimating the change in BP (mmHg) associated with a 1-SD increasea in BC (1,067 visits) and PM2.5 (949 visits) levels.b
| Change in BP (95% CI) | ||
|---|---|---|
| Air pollutant | SBP | DBP |
| BC | 1.46 (0.10 to 2.82) | 0.87 (0.15 to 1.59) |
| PM2.5 | 0.45 (−0.71 to 1.61) | 0.01 (−0.60 to 0.61) |
Corresponding to a 0.43-μg/m3 increase in 7-day average BC concentrations and a 4.98-μg/m3 increase in 7-day average PM2.5 concentrations.
All regression models are adjusted for age, cigarette smoking, pack-years of smoking, season of clinical visit, weekday of clinical visit, body mass index, diabetes status, statin use, fasting glucose level, 7-day moving average of temperature (linear and quadratic), 7-day moving average of relative humidity (linear and quadratic), hour of clinical visit, year of clinical visit, years of education, race/ethnicity, antihypertensive medication use, and daily alcohol intake.
p < 0.05.
Modification of the association between a 1-SD increase in BC and BP (mmHg) by SNPs related to antioxidative defense.a
| Change in BP (95% CI) | ||
|---|---|---|
| Genetic variant | SBP | DBP |
| Catalase C/T (rs480575) | ||
| CC ( | 1.27 (−0.77 to 3.30) | 0.62 (−0.49 to 1.74) |
| CT ( | 1.36 (−1.16 to 3.89) | 0.57 (−0.74 to 1.88) |
| TT ( | −0.53 (−5.27 to 4.21) | 0.59 (−2.12 to 3.29) |
| | 0.50 | 0.77 |
| Catalase C1167T (rs769217) | ||
| CC ( | 1.40 (−0.52 to 3.32) | 0.66 (−0.37 to 1.70) |
| CT ( | 1.49 (−1.05 to 4.04) | 0.59 (−0.77 to 1.94) |
| TT ( | 2.51 (−3.90 to 8.92) | 0.42 (−3.19 to 4.03) |
| | 0.37 | 0.95 |
| Catalase C(–262)T (rs1001179) | ||
| CC ( | 1.17 (−0.66 to 3.01) | 0.40 (−0.61 to 1.41) |
| CT ( | 0.99 (−1.75 to 3.73) | 0.97 (−0.39 to 2.33) |
| TT ( | 1.44 (−8.10 to 10.98) | 3.56 (−0.63 to 7.75) |
| | 0.65 | 0.42 |
| Catalase A/G (rs2284367) | ||
| AA ( | 1.35 (−0.58 to 3.28) | 0.68 (−0.36 to 1.72) |
| AG ( | 1.76 (−0.93 to 4.46) | 0.67 (−0.72 to 2.06) |
| GG ( | 7.20 (1.46 to 12.93) | 2.24 (−1.34 to 5.83) |
| | 0.61 | 0.80 |
| Catalase A/G (rs2300181) | ||
| AA ( | 2.05 (0.06 to 4.04) | 0.64 (−0.40 to 1.68) |
| AG ( | 0.56 (−1.91 to 3.02) | 0.38 (−0.87 to 1.64) |
| GG ( | 2.33 (−3.77 to 8.42) | 3.59 (−0.15 to 7.32) |
| | 0.28 | 0.31 |
| AA ( | 1.29 (−0.31 to 2.90) | 0.47 (−0.38 to 1.32) |
| AG ( | −0.24 (−5.15 to 4.68) | 1.08 (−1.37 to 3.52) |
| GG ( | — | — |
| | 0.33 | 0.66 |
| AA ( | 3.20 (0.91 to 5.49) | 0.83 (−0.36 to 2.01) |
| AG ( | −0.53 (−2.77 to 1.70) | 0.10 (−1.14 to 1.33) |
| GG ( | −0.29 (−6.44 to 5.85) | 2.48 (−0.26 to 5.21) |
| | 0.38 | 0.46 |
| CC ( | 1.85 (0.08 to 3.62) | 1.10 (0.15 to 2.04) |
| CT ( | 1.43 (−1.13 to 4.00) | 0.50 (−0.86 to 1.86) |
| TT ( | −6.28 (−21.07 to 8.52) | −1.23 (−8.46 to 6.01) |
| | 0.28 | 0.16 |
All counts reported correspond to number of study center visits. Interaction test results represent interactions between BC and variant allele number only. All regression models are adjusted for age, cigarette smoking, pack-years of smoking, season of clinical visit, weekday of clinical visit, body mass index, diabetes status, statin use, fasting glucose level, 7-day moving average of temperature (linear and quadratic), 7-day moving average of relative humidity (linear and quadratic), hour of clinical visit, year of clinical visit, years of education, race/ethnicity, antihypertensive medication use, and daily alcohol intake.
Insufficient sample size to obtain sample estimates.
Effect modification of the association between a 1-SD increase in BC concentrations and BP (mmHg) by gene variants related to oxidative stress.a
| Change in BP (95% CI) | ||
|---|---|---|
| Genetic variant | SBP | DBP |
| Present ( | 0.79 (−1.20 to 2.77) | 0.98 (−0.11 to 2.07) |
| Null ( | 1.84 (−0.12 to 3.81) | 0.76 (−0.23 to 1.74) |
| | 0.31 | 0.84 |
| Present ( | 1.26 (−0.38 to 2.91) | 0.86 (−0.02 to 1.74) |
| Null ( | 0.56 (−2.59 to 3.71) | −0.09 (−1.44 to 1.62) |
| | 0.91 | 0.80 |
| < 25 repeats ( | −0.33 (−4.80 to 4.14) | 1.16 (−1.01 to 3.32) |
| ≥ 25 repeats ( | 1.81 (0.34 to 3.29) | 0.81 (0.02 to 1.61) |
| | 0.64 | 0.78 |
All counts reported correspond to number of study center visits. Interaction test results represent interactions between BC and variant allele number only. All regression models are adjusted for age, cigarette smoking, pack-years of smoking, season of clinical visit, weekday of clinical visit, body mass index, diabetes status, statin use, fasting glucose level, 7-day moving average of temperature (linear and quadratic), 7-day moving average of relative humidity (linear and quadratic), hour of clinical visit, year of clinical visit, years of education, race/ethnicity, antihypertensive medication use, and daily alcohol intake.